2026-11-10 · 2026-11 / week-2

NRG’s $4B asset sale leaves its 2027 earnings bridge unresolved

NRG’s $4B asset sale leaves its 2027 earnings bridge unresolved

Classification: Reject / no-trade screen. NRG rose about 10.4% on Nov. 9 after reporting strong Q3 results, issuing 2027 guidance, and agreeing to sell 4.9 GW of gas generation for $4 billion. The new guidance explicitly excludes the sale’s expected effects. That leaves an important post-sale earnings question, but the current evidence does not support a 10% base-case decline, a 5% adverse bound, or a 2:1 reward-to-risk ratio.

Run time: Nov. 10, 2026, 08:49 Singapore time (UTC+08:00).

Market observation: NRG regular-session close of $97.50 on Nov. 9, 2026, 3:59:56 p.m. EST (20:59:56 UTC), after the company released its results and sale agreement before the open.

Scope: U.S.-listed short opportunities only. Research screen, not a broker order.

Opportunity Ranking

Candidates are ranked for current research value. None qualifies as a short.

Rank Candidate Direction Mispricing under review Evidence freshness Catalyst window Positioning 10/5 status Tradeability Main rejection risk
1 NRG Energy (NRG) Short screen $97.50 equals about 10.77x the midpoint of 2027 adjusted EPS guidance, but that guidance excludes the new sale. High: Nov. 9 issuer results and sale agreement; Nov. 9 close. Regulatory review and targeted Q2 2027 close, then updated guidance. Price rose about 10.4%; current short interest, borrow, options and ownership were not verified. Reject: midpoint case is flat; high-EPS case implies an 11.0% adverse rise. NYSE common stock; live spread, depth, locate, borrow and exit capacity unverified. The assets may have been sold at an attractive multiple, with cash used for debt reduction and repurchases.
2 Occidental Petroleum (OXY) Short screen Q3 realized crude prices fell 11% sequentially, but the company generated $2.8B of free cash flow before working capital and reduced principal debt to $10B. High: Nov. 9 issuer results and same-day close; after-hours quote captured separately. First post-release regular session on Nov. 10; future commodity and production reports. Position and borrow data were not verified. Reject: no sourced 10% base decline or ≤5% adverse bound. NYSE common stock; event quote feeds differ and short gates are incomplete. Production exceeded guidance and cash generation remained strong.
3 Constellation Energy (CEG) Short screen Q3 adjusted operating EPS rose to $5.06 from $3.04; the company raised full-year guidance and added long-term nuclear agreements. High: Nov. 9 issuer release and market close. Future contract and uprate milestones; no near-term deterioration is established. Nov. 9 price rose about 10.5%; current short and borrow data were not verified. Reject: positive new guide and contracts leave no sourced 10/5 short case. Nasdaq common stock; live short-specific execution data are missing. Issuer attributes the Q3 rise mainly to favorable market/portfolio conditions and Calpine, but guide and long contracts still support the countercase.
4 SPDR S&P 500 ETF (SPY) Broad-market control Nov. 9 close rose 2.36%, a broad-market rebound rather than an issuer-specific disagreement. High: Nov. 9 historical daily close. No issuer-specific catalyst. Index flows and dealer exposures were not reviewed. Reject: no differentiated short thesis. Liquid ETF; no short execution review was performed. A broad-market short would be a macro view without a sourced edge.

HNST and CERT were screened as comparators in the Nov. 9 FSLY article. Their latest issuer releases were Nov. 5, so this run does not count their unchanged evidence as fresh candidates. NRG, OXY and CEG each have a new Nov. 9 result boundary. Their sources and price observations appear below.

The Oct. 7 CEG screen covered Google agreements before this Q3 report; this run uses new quarterly results and raised 2026 guidance. NRG and OXY appeared only as pre-results comparators in the Nov. 9 Berkshire screen; this run uses NRG’s new Q3 results and sale agreement and OXY’s new Q3 release. These are updated evidence boundaries, not copies of the earlier screens.

Selected opportunity: NRG is the highest-information rejected short screen, not the best executable opportunity.

Why this one now: The prior Nov. 9 Berkshire screen included NRG only as a pre-results comparator. The new Q3 release, 2027 guidance, and definitive sale agreement materially change the evidence boundary. No standalone NRG article or signal existed in the archive.

What should surprise the reader: NRG’s new $5.50B–$6.00B 2027 adjusted EBITDA guide is not sale-adjusted. The company says the sold assets were valued at 8.0x their estimated 2027 adjusted EBITDA. That implies about $500M of annualized EBITDA attached to the assets, roughly 8.7% of the guide midpoint, before considering closing timing, proceeds, buybacks, debt reduction, or other changes. NRG has not yet published the revised guidance needed to net those effects.

Why This Can Move More Than 5% Soon

The Nov. 9 response already exceeded 5%: NRG closed about 10.4% above the prior regular-session close after a combined earnings, outlook, and asset-sale announcement. That price move establishes volatility around the new information; it does not establish that the market is wrong or that another 10% move is more likely down than up.

The next material company-specific test is conditional. The $4B sale is targeted to close in Q2 2027 and requires HSR, FERC, and New York State Public Service Commission approvals. NRG says it will update 2027 guidance after the close. Until then, the pre-sale earnings guide and proposed use of proceeds cannot be reconciled into a post-sale per-share forecast. A delay, failed approval, replacement investment, or higher realized value for retained generation could each move the price in either direction.

The Setup

NRG reported Q3 adjusted EBITDA of $2.013B, up $808M year over year, and adjusted EPS of $4.68 versus $2.78. The same release says the quarter benefited from the acquired LS Power portfolio, higher East capacity prices, higher Texas margins and favorable weather. Higher interest and depreciation on acquired assets, plus unrealized hedge losses, offset some gains. Texas nine-month adjusted EBITDA was nearly flat year over year at $1.615B versus $1.618B; East increased to $1.547B from $680M, largely reflecting the acquisition and capacity prices. Q3 growth should not be annualized without the acquisition, weather, and segment bridges. NRG Q3 results

NRG agreed to sell six gas generation assets totaling 4.9 GW to LS Power for $4B cash, subject to working-capital adjustments. The company says the sale will leave it with 20 GW of generation. It describes the deal as an implied 8.0x 2027 EV/adjusted EBITDA valuation. Dividing $4B by 8.0x gives a Desk estimate of roughly $500M of asset-level 2027 adjusted EBITDA. This is not GAAP earnings, a company-reported standalone number, or a full-year 2027 earnings reduction: the sale is targeted to close in Q2, and the accounting, timing, and proceeds will change the bridge. NRG sale announcement

The proposed capital allocation is meaningful counterevidence to a short. NRG’s 2027 base plan includes $1B of debt reduction, $1B of repurchases, and an 8% dividend increase to $2.05 per share. Sale proceeds are expected to support $3B of repurchases across 2026–2027, including another $1B expected to begin before 2026 ends, and $3B of total planned 2027 debt reduction after the sale closes. The remaining expected $1B is reserved for contracted growth or additional debt reduction. These are plans, not completed uses of cash. NRG had completed $977M of its earlier 2026 repurchase plan through Oct. 31. The declared current quarterly dividend is $0.475 per share; a 2027 increase is not yet a declared payment. NRG Q3 results

The capital structure keeps the bear case alive but does not finish it. The latest 10-Q reports $23.048B of long-term debt including current maturities, and $148M of cash at Sept. 30, a simple debt-less-cash calculation of about $22.9B before other claims and entity structure. Reported total liquidity was $6.027B, including $5.850B of revolving and collateral-facility availability; that is not $6B of unrestricted cash. Common shares outstanding were 210.021M on Oct. 31. NRG approved another $1B repurchase authorization on Nov. 6; no post-Oct. 31 share count or purchases are available to show its effect. NRG Q3 Form 10-Q

The Market Price

ChartExchange’s Nov. 9 historical row reports a $97.50 close, versus $88.29 on Nov. 6, a 10.43% rise. Its at-close tile was also $97.50. This is a regular-session reference, not an executable entry. I do not use volume to infer short covering or forced flow. NRG historical prices

For context, ChartExchange’s Nov. 9 rows show CEG at $276.21, up 10.51%, and OXY at $55.78, down 1.06%. CEG’s release attributes Q3 adjusted operating earnings primarily to favorable market/portfolio conditions and the addition of Calpine, so the year-over-year EPS comparison is not a same-asset growth rate. StockAnalysis’s S&P Global-sourced OXY history reports a $55.81 close; its latest separate after-hours observation retrieved was $55.84 at 7:16 p.m. EST, while ChartExchange’s earlier 4:54 p.m. snapshot was $55.65. These quotes are separate and not averaged. OXY’s first post-release regular session is Nov. 10 and has not been observed at this run time; its after-hours mark is reference context only. ChartExchange’s SPY row shows $752.72, up 2.37%. CEG historical prices · OXY historical prices · OXY cross-check · SPY historical prices

The Mispricing

At $97.50, NRG trades at about 10.77x the midpoint of its new $8.05–$10.05 2027 adjusted EPS range: $97.50 / $9.05 = 10.77x. This is a Desk calculation using the issuer’s non-GAAP guidance. It is not a consensus multiple, GAAP P/E, or proof of overvaluation. The guide explicitly excludes the expected sale effects. Potential debt reduction and repurchases could support per-share earnings, while disposed generation removes earnings and capacity. The split between those effects is not yet disclosed.

The short interpretation is that the 10.4% rally capitalizes a favorable sale multiple and buyback plans before the market sees post-sale earnings. The counterinterpretation is stronger today: the sale monetizes assets at a stated 8x multiple, NRG retains 20 GW of generation, and it has a defined debt and capital-return plan. Both readings are plausible. The missing sale-adjusted EPS bridge prevents a falsifiable current claim that NRG is priced for too much earnings.

The Positioning

Observed positioning is limited to the price gap. It does not identify who bought or sold. I did not verify current beneficial ownership, FINRA short interest for the latest settlement, borrow availability or cost, recall terms, options positioning, dealer exposure, fund flows, live spread, order-book depth, venue quality, or exit liquidity. Short interest and short-sale volume are not interchangeable. I make no squeeze or crowding claim; the missing short-specific evidence blocks execution.

Catalyst Ladder

Step State and timing Observable test Failure or delay
First regular-session response Completed Nov. 9 after the pre-market Q3 and sale announcements. NRG closed about 10.4% higher than Nov. 6. Compare later closes with the new guide, not with the pre-event price alone. The positive response is not proof of lasting earnings or sale value.
Regulatory approvals Pending; sale targeted for Q2 2027. HSR, FERC, and NYSPSC approvals are required. Verify each approval, purchase-price adjustments, closing date, and actual proceeds. Delay or failure leaves NRG with the assets and invalidates a sale-completion thesis.
Updated 2027 guidance NRG says it will update guidance and its capital plan after the sale closes; exact date is unknown. Reconcile disposed EBITDA, debt reduction, repurchases, retained generation, and per-share earnings. If the sale closes without a usable post-sale bridge, the thesis remains unproven.

The cheapest falsification test is the first post-close guidance table against the current $5.50B–$6.00B pre-sale EBITDA and $8.05–$10.05 pre-sale EPS ranges. Before that release, the short thesis depends on a forecast the company has not supplied.

Price Target and Probability Map

This is a reference-only sensitivity through Sept. 30, 2027, spanning the announced Q2 sale target and time for a post-close guide update. The exact price-implied adjusted-EPS multiple is $97.50 / $9.05 = 10.7735x, shown as 10.77x elsewhere. Applying that exact factor to the low, midpoint, and high of NRG’s 2027 adjusted EPS guide gives $8.05 × 10.7735 = $86.73, $9.05 × 10.7735 = $97.50, and $10.05 × 10.7735 = $108.27. The guide excludes sale effects, so these are not post-sale fair values or forecasts.

The 20% / 60% / 20% weights are low-confidence subjective weights: the midpoint receives the highest weight because it is the issuer’s stated midpoint, while the equally spaced guide endpoints receive equal tail weights. NRG supplies no probability distribution and the Desk has no comparable guidance-hit-rate series for this scenario. These weights are a transparent sensitivity convention, not observed frequencies or calibrated probabilities.

Scenario Probability Target / level Short return Horizon Conditions Evidence quality
Top case 20% $86.73 +11.0% Through Sept. 30, 2027 Adjusted EPS reaches the low end while the current 10.77x multiple holds. Low: issuer range is pre-sale; multiple is held constant.
Base case 60% $97.50 0.0% Through Sept. 30, 2027 Adjusted EPS reaches the midpoint and the current multiple holds. Low: sale-adjusted guide and market-implied expectations are unknown.
Bottom case 20% $108.27 -11.0% Through Sept. 30, 2027 Adjusted EPS reaches the high end while the current multiple holds. Low: issuer range is pre-sale; buybacks and debt reduction are not modeled.
Invalidation n/a Re-underwrite after the post-sale guide n/a Following a Q2 2027 close, if completed Replace this sensitivity with the actual sale-adjusted earnings, share count, debt, and capital-return plan. Medium for the test; future results unknown.

Probability-weighted expected value: $97.50 reference price; 0.0% gross short return before costs. The weights sum to 100%.

Current market level and timestamp: $97.50, Nov. 9, 2026, 3:59:56 p.m. EST (20:59:56 UTC), regular-session close.

Primary instrument: NRG common stock, NYSE; research only.

10/5 favorable base move: 0.0% decline, below 10%. The low-EPS case is not the highest-probability case.

10/5 credible adverse move: 11.0% underlying rise in the high-EPS case, beyond 5%. Actual upside could exceed this sensitivity.

Gross reward/adverse ratio: 0.00:1.

10/5 measurement basis: Reference-only; entry.price is null.

10/5 status: Reject / no trade. The map has no positive price-only expected value before costs; short carry, dividend payments, spread, borrow, and recall costs are unquantified.

Confidence: Low. The key earnings guidance excludes the transaction, probabilities are subjective, and current positioning and execution evidence are missing.

10/5 Asymmetry Gate

The highest-probability case is flat, below the required 10% base decline. The high-EPS case is an 11.0% rise, beyond the 5% adverse limit, and the gross reward-to-adverse ratio is 0:1. The weighted price-only return is 0% before borrow, dividend, spread, slippage, and recall costs. A short fails before execution review; missing locate and liquidity evidence further blocks entry.

The Kill Shot

Strongest counterargument: The sale converts capacity into cash at a company-stated 8x EBITDA, while the retained 20 GW still includes major ERCOT and PJM positions. NRG plans to reduce debt and repurchase shares. Its Q3 and 2027 outlook were strong, while CEG also reported higher Q3 adjusted earnings and raised its annual guide on the same date. The market may be recognizing private scarcity value and capital discipline rather than extrapolating a short-lived earnings peak. NRG sale announcement · CEG Q3 results

Load-bearing assumption: The market is assigning value to the proceeds and buyback plan without adequately deducting the earnings removed with the 4.9 GW portfolio. The assumption is fragile because NRG has not issued a post-sale forecast, and debt reduction or repurchases can offset some of the earnings loss. The 8x value is management’s estimate for the assets, not an independent whole-company multiple.

What Could Go Wrong

The sale could close on time at the stated valuation, lower debt, and reduce the share count. Demand, capacity prices, weather, and natural-gas prices can change both retained-generation earnings and investor expectations. NRG’s Q3 includes acquisition contributions and favorable weather; repeating the quarter is not assured. A market can also keep paying a higher multiple for power generation even if the guide is merely met.

A short can lose more than the modeled 11.0% if earnings exceed the guide, transaction approvals improve the outlook, or demand drives a re-rating. Gaps, halts, recalls, unavailable borrow, dividends owed, and weak exit liquidity can compound losses. No stop price caps those risks. No option chain, defined-loss alternative, locate, borrow fee, recall term, spread, depth, or exit capacity was verified.

What Would Prove This Wrong

Retire the short screen if the transaction closes on schedule and the updated guide shows that debt reduction, repurchases, or retained generation preserve or lift adjusted EPS near or above the $9.05 midpoint without a lower valuation. Rebuild the model if regulators delay or reject the sale, the sale price changes materially, or NRG replaces the assets with contracted projects. A price move alone is not proof of either outcome.

No-Trade Strategy

There is no pending order and no entry. Keep entry.price null and execution disabled. Re-screen after the first sale approval or revised closing terms, then after the actual close and updated 2027 guide. A future short review must still show a ≥10% highest-probability decline, a credible adverse rise no greater than 5%, at least 2:1 gross reward-to-adverse risk, and positive expected value after dividend, borrow, spread, slippage, and recall costs. Options, leverage, margin, market orders, and short selling without a verified locate are outside this screen.

Research Quality Scorecard

Criterion Score Evidence-based reason
Market disagreement 3/5 A new sale and guidance gap is real, but the $97.50 price does not establish excessive earnings expectations.
Evidence base 5/5 Nov. 9 NRG and peer releases plus same-session closes were read; source price fields conflict slightly.
Positioning and flows 2/5 Price action is known; short interest, borrow, options, ownership, and forced flows are not.
Catalyst path 3/5 Approval, closing, and updated guidance are observable but conditional and months away.
Payoff architecture 1/5 The reference sensitivity has a flat base and 11.0% adverse rise; the post-sale model is missing.
Invalidation discipline 4/5 Approval, closing, actual proceeds, debt, repurchases, and the revised guide are monitorable.
Differentiated insight 4/5 The key issue is that 2027 guidance expressly excludes the sale, despite the rally.
Client value 3/5 The screen separates asset proceeds from the earnings removed and sets a concrete no-trade test.
Total 25/40 Reject / no trade; the failed 10/5 gate controls classification.

Bottom Line

NRG sold a meaningful portfolio at a stated 8x asset EBITDA multiple and rose about 10.4% after announcing it. The unresolved item is not whether the sale is large; it is the updated per-share earnings after the sale, debt reduction, and buybacks. With a flat midpoint case, an 11.0% adverse sensitivity, and unverified short execution, the right current classification is Reject / no trade.

Sources

  1. NRG Q3 2026 results, 2027 guidance, and capital allocation, Nov. 9
  2. NRG $4B asset sale terms, Nov. 9
  3. NRG Q3 Form 10-Q, Sept. 30
  4. NRG Nov. 9 historical close, ChartExchange
  5. Occidental Q3 2026 results, Nov. 9
  6. OXY historical closes and after-hours snapshot, StockAnalysis
  7. OXY historical closes and after-hours cross-check, ChartExchange
  8. Constellation Q3 2026 results and raised outlook, Nov. 9
  9. CEG Nov. 9 historical close, ChartExchange
  10. SPY Nov. 9 historical close, ChartExchange

AI Illustration Prompt

Create a restrained financial-documentary illustration for The Mispricing Desk: a gas-generation portfolio marked “4.9 GW” moving across a transaction table for “$4B / 8.0x,” while a separate ledger shows “2027 EPS $8.05–$10.05” stamped “SALE EFFECT EXCLUDED.” In the distance, retain a smaller power fleet marked “20 GW,” with two blank approval boxes labeled “FERC” and “NYPSC.” Use muted steel blue, warm paper, and low-saturation amber; precise industrial detail, no company logos, no trading screens or rising arrows. Leave quiet space around the ledger and add a subtle readable “The Mispricing Desk” watermark.